Products Released for Forensic Drug Testing in Laboratories Worldwide

By LabMedica International staff writers
Posted on 17 Feb 2011
A global diagnostic company has released a number of new products for forensic drug testing in public and private laboratories worldwide.

A Drugs of Abuse array (DoA I+) enables all tests to be measured simultaneously from a single sample. Tests available include; amphetamine, methamphetamine, barbiturates, benzodiazepine 1 and 2, cannabinoids, cocaine metabolite, methadone, opiates and phencyclidine, buprenorphine, fentanyl, generic opioids, ketamine, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA, also known as ecstasy), methaqualone, oxycodone 1 and 2, propoxyphene, buprenorphine, and tricyclic antidepressants (TCAs).

Randox (Crumlin, United Kingdom) Biochip array technology has created a reduction for time spent on individual tests. A number of drug analytes are grouped and carried out on a biochip to allow for consolidated testing. The multimarker process allows toxicologists to determine a substantial amount of information from a small volume of sample. The technology incorporates enzyme-linked immunosorbent assay (ELISA) principles, providing accurate and reliable results.

Antibodies are manufactured by Randox onsite allowing the company to sustain quality while continually expanding its test portfolio. Drug testing solutions are also offered for clinical toxicology, workplace drug testing, and onsite testing environments. Randox manufactures high quality diagnostic products for laboratories worldwide.

Related Links:
Randox



Latest Immunology News